HomeCompareCNVVY vs SBUX

CNVVY vs SBUX: Dividend Comparison 2026

CNVVY yields 2.51% · SBUX yields 2.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNVVY wins by $176.68M in total portfolio value
10 years
CNVVY
CNVVY
● Live price
2.51%
Share price
$11.56
Annual div
$0.29
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.83M
Annual income
$164,256,279.23
Full CNVVY calculator →
SBUX
SBUX
● Live price
2.75%
Share price
$89.59
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$157.5K
Annual income
$65,840.13
Full SBUX calculator →

Portfolio growth — CNVVY vs SBUX

📍 CNVVY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNVVYSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNVVY + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNVVY pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNVVY
Annual income on $10K today (after 15% tax)
$213.24/yr
After 10yr DRIP, annual income (after tax)
$139,617,837.35/yr
SBUX
Annual income on $10K today (after 15% tax)
$233.40/yr
After 10yr DRIP, annual income (after tax)
$55,964.11/yr
At 15% tax rate, CNVVY beats the other by $139,561,873.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNVVY + SBUX for your $10,000?

CNVVY: 50%SBUX: 50%
100% SBUX50/50100% CNVVY
Portfolio after 10yr
$88.50M
Annual income
$82,161,059.68/yr
Blended yield
92.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CNVVY
Analyst Ratings
6
Buy
Consensus: Buy
Altman Z
4.0
Piotroski
7/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+16.1% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNVVY buys
0
SBUX buys
0
No recent congressional trades found for CNVVY or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNVVYSBUX
Forward yield2.51%2.75%
Annual dividend / share$0.29$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%48.3%
Portfolio after 10y$176.83M$157.5K
Annual income after 10y$164,256,279.23$65,840.13
Total dividends collected$175.87M$127.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyBuy

Year-by-year: CNVVY vs SBUX ($10,000, DRIP)

YearCNVVY PortfolioCNVVY Income/yrSBUX PortfolioSBUX Income/yrGap
1← crossover$11,202$501.73$11,107$407.21+$95.00CNVVY
2$13,036$1,050.51$12,512$626.87+$524.00CNVVY
3$16,234$2,285.17$14,366$978.69+$1.9KCNVVY
4$22,690$5,319.08$16,929$1,557.50+$5.8KCNVVY
5$38,174$13,895.72$20,658$2,543.80+$17.5KCNVVY
6$84,544$43,698.21$26,406$4,302.22+$58.1KCNVVY
7$271,358$180,896.29$35,877$7,622.00+$235.5KCNVVY
8$1,375,621$1,085,267.30$52,741$14,352.64+$1.32MCNVVY
9$11,755,358$10,283,443.92$85,676$29,243.03+$11.67MCNVVY
10$176,834,512$164,256,279.23$157,513$65,840.13+$176.68MCNVVY

CNVVY vs SBUX: Complete Analysis 2026

CNVVYStock

ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, immobility, and venous disease, as well as from traumatic injury, burns, invasive surgery, and other causes. The company also provides devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, bladder cancer, obesity, and other causes. In addition, it offers continence and critical care products, including intermittent urinary catheters; and products for people with urinary continence issues related to spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders, as well as devices and products used in intensive care units and hospital settings. Further, the company provides advanced systems for managing acute fecal incontinence, as well as for monitoring urine production output and intra-abdominal pressure; and various disposable medical devices, such as wound drainage systems, urine collection bags and catheters, airway management and oxygen/aerosol therapy devices, suction handles and tubes, gastroenterology tubes, and securement devices. Additionally, it offers disposable infusion sets to manufacturers of insulin pumps for diabetes, as well as similar pumps that are used in continuous infusion treatments for other conditions; and various products to hospital and home healthcare markets. The company sells its products to pharmacies, hospitals, and other acute and post-acute healthcare service providers directly or through distributors and wholesalers. It serves a range of customers, including healthcare providers, patients, and manufacturers. The company was founded in 1978 and is headquartered in Reading, the United Kingdom.

Full CNVVY Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CNVVY vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNVVY vs SCHDCNVVY vs JEPICNVVY vs OCNVVY vs KOCNVVY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.